Ellen Cavaleri
Investor Relations Contact bij LYRA THERAPEUTICS, INC.
Profiel
Ms. Ellen Cavaleri is a Senior VP-Investor Relations & Communications at Lyra Therapeutics, Inc. Ms. Cavaleri was previously employed as an Investor Relations Contact by Kadmon Holdings, Inc. She received her undergraduate degree from Vanderbilt University and an MBA from New York University.
Actieve functies van Ellen Cavaleri
Bedrijven | Functie | Begin |
---|---|---|
LYRA THERAPEUTICS, INC. | Investor Relations Contact | 01-01-2022 |
Eerdere bekende functies van Ellen Cavaleri
Bedrijven | Functie | Einde |
---|---|---|
KADMON HOLDINGS, INC. | Investor Relations Contact | - |
Opleiding van Ellen Cavaleri
Vanderbilt University | Undergraduate Degree |
New York University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
LYRA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Kadmon Holdings, Inc.
Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |